EX

Exevir

2 known investors

exevir.com ↗

ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue. Its modular, multi-specific antibody platform targets vulnerable patients including the immunocompromised.

Investors · 2

FU

Fund+Leuven · $5.5M – $16.5M

V-

V-Bio VenturesGhent · $270K – $2.2M